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Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide, with a wide spectrum of risk factors.
Owing to changes in the prevalence of major risk factors such
as hepatitis and non alcoholic steatohepatitis, there are several
classification systems for HCC developed from different patient
populations. It is well established that HCC develops as a conse-
quence of underlying chronic liver disease (CLD). Therefore, there
are two co-existing competing causes of morbidity and mortality,
poor liver condition and cancer. The two-disease state signifi-
cantly affects prognosis, which ultimately dictates treatment deci-
sions and stratification of patients with HCC.
Hence, most of the currently reported 18 HCC prognostic
staging systems, as presented at the conference, include factors
related to assessment of the liver condition, in addition to the
tumor parameters.1 However, construction of an internationally
accepted and preferentially used staging system for HCC has
proven to be a daunting task.
Therefore, there was no consensus on a single staging system
that can predict prognosis reliably in all patients’ populations,
with different predisposing factors and tumor and CLD stage. The
conference adeptly describes the problems with international
communication on this very widespread cancer related to variable
staging methods and different terminology and practice standards
in different parts of the world.
Thus, there is an unmet need for prospective validation of
different scoring systems within similar patient populations, and
risk factors, an approach which will need large number of patients
to draw firm conclusions. Furthermore, advances in molecular
approaches, using tissue and blood samples assays, to identify
biologic factors related to outcome, are expected to minimize
the marked heterogeneity noted in all scoring systems available.
Further advances in the circulating biomarkers research are
important in this setting, since some patients are not subjected to
biopsy prior to treatment based on the criteria set forth by the
practice committee of the American Association for the Study of
Liver Diseases (AASLD),2 and adopted by many centers around
the world.
In addition, the imaging of HCC, as presented in this confer-
ence, is a reflection of current practice with inclusion of CT and
MR scan, including appropriate and in depth documentation of
imaging sequences and the use of all possible contrast agents on
both modalities. However, the benefit and superior performance
of state of the art MRI technology is emphasized, including
MRI elastography, for evaluation of liver fibrosis, and diffusion-
weighted imaging (DWI).
With the addition of these newer techniques, both sensitivity
and specificity for HCC evaluation are improved. An appropriate
cautionary comment is made regarding the risk of radiation
exposure with the choice of CT scan in this CLD population
who require many imaging tests over time. Although the ques-
tion of surveillance is not addressed, diagnosis is appropriately
covered. The omission of contrast enhanced ultrasound (CEUS)
reflects the American environment where ultrasound and CEUS
are not part of any investigative situation related to lack of
Food and Drug Administration approval for ultrasound contrast
agents in spite of their approval in at least 70 other countries
of the world.3,4 Because of enthusiastic adoption of CEUS in
the international community, the AASLD acknowledges the role
of ultrasound in the diagnosis of HCC and the investigation
of small nodules found on surveillance scans in those at high
risk for HCC.2
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In considering a liver resection for HCC, there is no strict
maximum size nor tumor number that contraindicates resection;
however, patients with larger tumors and those with multifocal
disease or tumor invasion into a portal or hepatic vein have a
higher incidence of recurrence. Two important considerations for
resection are patient’s ‘hepatic risk’ (assessment of liver function
and presence of portal hypertension) and the size of the future
liver remnant (FLR). In patients with cirrhosis, both the Child-
Pugh and the MELD scores provide a valuable assessment of
normal liver function and PHT. More sensitive determinants
of PHT include thrombocytopenia <100,000, or radiologic evi-
dence of ascites, splenomegaly or portosystemic collateral veins.
Additionally in cirrhotics, if the volumetric measurement of the
FLR is <40% of the total liver volume (TLV), a portal vein embo-
lization to induce hypertrophy of the FLR achieving at least a
10% increase in the FLV to at least 40% of the TLV should be
performed to reduce the risk of liver failure following resection.5–7
Finally, the treatment of HCC and the reasons for selection of
one treatment over another provides a fascinating picture of the
difficult questions which arise in the management of the patient
whose liver has CLD and is found to have such a tumor. Therefore,
the efforts to standardize different aspects of HCC management,
from liver nomenclature to staging and treatment choices were
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